Page 17 - emap_newsletter_V2
P. 17
eMAP – electronic EHA Medical HemAtology Program
P949 A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY,
P959 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR
P970 MAGNETISMM-3
P971
P977 CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE
P1446 MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE
P1739 ANALYSES AND UPDATED CLINICAL DATA
P1740
SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE
TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION
COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-
CLASS EXPOSED MULTIPLE MYELOMA
BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE
MYELOMA
PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY
MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY
(R/R) MULTIPLE MYELOMA (MM)
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/
REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE
1B/2A OPEN-LABEL DOSE ESCALATION STUDY
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
(RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS. BELANTAMAB MAFODOTIN: A MATCHING-
ADJUSTED INDIRECT COMPARISON STUDY
POST-TEST Please give your feedback.
Click here to test your knowledge It will only take a minute!
and retention of novel CAR T data
after reviewing this newsletter Visit this Discussion Forum for any
summary questions or to chat with your peers.
OPPORTUNITY TO EARN SECTION 3 CREDITS (ASSESSMENT ACTIVITY)
You are invited to participate in a Chart Audit and Feedback Assessment Activity regarding the management of your patients
with either LBCL or RRMM, and to subsequently reflect on your practice. Not only will you earn Section 3 credits, you will also
help to improve the management of your patients with blood cancers.
Instructions:
• Earn Section 3 credits by completing a chart audit for a minimum of 10 eligible patients. Patients you select for this self-
reflective program should have a confirmed diagnosis of LBCL or RRMM. You will be able to claim three credits for each
hour you spend completing the initiative.
• To claim MOC credit for this assessment activity, visit MAINPORT and complete the fields under Section 3: Chart Audit
and Feedback, for three credits per hour.
CLICK HERE FOR MORE INFORMATION REGARDING SECTION 3 CHART AUDITS
TABLE OF CONTENTS 17
